Paragraf Is Finding A Way To Bring Graphene To Diagnostics

The UK-based company is creating a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.

Network Sphere
A 3d illustration of a graphene tube • Source: Shutterstock

In 2004, graphene was physically produced for the first time at Manchester University by using Sellotape to shear off thin layers of carbon. Its discoverers, Andre Geim and Kostya Novoselov went on to win a Noble Prize in physics for their findings in 2010. Since then, claims that electronics, vehicles and medicine will be transformed by the carbon-based material said to be both harder and lighter than steel, highly conductive and incredibly light have been rampant. 

However, expensive to produce reliably, graphene has had little impact on industry to date, and very few graphene

One company hoping to change this is Paragraf, a UK-based innovator that is working on a range of graphene-based Hall-effect sensors for use in a variety of specialties,

More from Financing

More from Business

The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

GE HealthCare Warns Of $500M Tariff Hit In 2025, Eyes Recovery in 2026

 
• By 

GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By 

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.